Abstract

SummaryAn inactivated preparation of rhinovirus type 13 administered subcutaneously to 29 antibody-free volunteers in three 1.0-ml doses at two week intervals resulted in rapid appearance of high titers of homotypic serum neutralizing antibody in 100% of volunteers. Parallel responses were observed in 17 other volunteeers with preexisting antibody. Antibody in nasal secretions was detected in 38% and 59% of vaccinees, respectively. Challenge of 14 vaccinees with 3 TCid50 of live rhinovirus type 13 resulted in similar rates of infection and illness, as compared to 13 nonvaccinated controls, but there was significant reduction in virus shedding, severity of illness and duration of illness in the vaccinees.We wish to thank Terrel D. Hutto, Warden, Clive Aldridge and Hudie Cottrell, Medical Officers, Ramsey Unit, Texas Department of Corrections, for their help in the volunteer program; Peggy Kleyle for her technical work; and Dr. David Alling for the statistical tests.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call